David Dai
Stock Analyst at UBS
(0.83)
# 3,834
Out of 4,941 analysts
24
Total ratings
31.82%
Success rate
-20.03%
Average return
Main Sectors:
Top Industries:
Stocks Rated by David Dai
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| SNDX Syndax Pharmaceuticals | Maintains: Buy | $37 → $35 | $12.73 | +174.94% | 2 | Jul 15, 2025 | |
| NRIX Nurix Therapeutics | Maintains: Buy | $30 → $26 | $9.76 | +166.39% | 2 | Jul 10, 2025 | |
| SMMT Summit Therapeutics | Initiates: Buy | $30 | $24.84 | +20.77% | 1 | Jul 1, 2025 | |
| IOVA Iovance Biotherapeutics | Downgrades: Neutral | $17 → $2 | $2.12 | -5.44% | 2 | May 16, 2025 | |
| CGEM Cullinan Therapeutics | Maintains: Buy | $30 → $24 | $7.21 | +232.87% | 2 | May 12, 2025 | |
| NUVL Nuvalent | Upgrades: Buy | $100 | $76.11 | +31.39% | 2 | Mar 14, 2025 | |
| KURA Kura Oncology | Maintains: Buy | $27 → $14 | $5.97 | +134.70% | 2 | Mar 6, 2025 | |
| IMCR Immunocore Holdings | Initiates: Sell | $24 | $32.31 | -25.72% | 1 | Oct 24, 2024 | |
| CATX Perspective Therapeutics | Initiates: Buy | $20 | $3.78 | +429.80% | 1 | Oct 24, 2024 | |
| MRUS Merus | Initiates: Buy | $72 | $64.37 | +11.85% | 1 | Oct 24, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $69 | $24.02 | +187.26% | 1 | Oct 24, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $50 | $23.51 | +112.68% | 1 | Oct 24, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $60 | $24.44 | +145.50% | 1 | Oct 24, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $28 | $0.61 | +4,471.05% | 1 | Mar 31, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $40 | $21.49 | +86.13% | 1 | Mar 16, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $40 | $1.49 | +2,593.60% | 1 | Feb 4, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $50 | $1.98 | +2,431.65% | 1 | Nov 18, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $41 → $52 | $31.99 | +62.55% | 1 | Mar 17, 2020 |
Syndax Pharmaceuticals
Jul 15, 2025
Maintains: Buy
Price Target: $37 → $35
Current: $12.73
Upside: +174.94%
Nurix Therapeutics
Jul 10, 2025
Maintains: Buy
Price Target: $30 → $26
Current: $9.76
Upside: +166.39%
Summit Therapeutics
Jul 1, 2025
Initiates: Buy
Price Target: $30
Current: $24.84
Upside: +20.77%
Iovance Biotherapeutics
May 16, 2025
Downgrades: Neutral
Price Target: $17 → $2
Current: $2.12
Upside: -5.44%
Cullinan Therapeutics
May 12, 2025
Maintains: Buy
Price Target: $30 → $24
Current: $7.21
Upside: +232.87%
Nuvalent
Mar 14, 2025
Upgrades: Buy
Price Target: $100
Current: $76.11
Upside: +31.39%
Kura Oncology
Mar 6, 2025
Maintains: Buy
Price Target: $27 → $14
Current: $5.97
Upside: +134.70%
Immunocore Holdings
Oct 24, 2024
Initiates: Sell
Price Target: $24
Current: $32.31
Upside: -25.72%
Perspective Therapeutics
Oct 24, 2024
Initiates: Buy
Price Target: $20
Current: $3.78
Upside: +429.80%
Merus
Oct 24, 2024
Initiates: Buy
Price Target: $72
Current: $64.37
Upside: +11.85%
Oct 24, 2024
Initiates: Buy
Price Target: $69
Current: $24.02
Upside: +187.26%
Oct 24, 2024
Initiates: Buy
Price Target: $50
Current: $23.51
Upside: +112.68%
Oct 24, 2024
Initiates: Buy
Price Target: $60
Current: $24.44
Upside: +145.50%
Mar 31, 2022
Initiates: Outperform
Price Target: $28
Current: $0.61
Upside: +4,471.05%
Mar 16, 2022
Initiates: Outperform
Price Target: $40
Current: $21.49
Upside: +86.13%
Feb 4, 2022
Initiates: Outperform
Price Target: $40
Current: $1.49
Upside: +2,593.60%
Nov 18, 2021
Initiates: Outperform
Price Target: $50
Current: $1.98
Upside: +2,431.65%
Mar 17, 2020
Upgrades: Outperform
Price Target: $41 → $52
Current: $31.99
Upside: +62.55%